Divulging the Next Generation of TGF-β Therapeutics

8:25 am Chair’s Opening Remarks

8:30 am Revealing the Latest Updates in the TGF-β for Immuno-Oncology Pipeline

  • Shannon Turley Vice President - Immunology & OMNI Biomarker Discovery, Genentech Inc


  • Discussing the cell types that the compound has a mechanism of action on
  • What can a TGF-β inhibitor do relative to other targeted therapies or checkpoint inhibitors?
  • Looking to the future for TGF-β drug development

9:00 am The Road to Success: Selectively Targeting TGF-β for Antifibrotic Drug Development & Harnessing the Translational Insights for Immuno-Oncology

  • Scott Turner Senior Vice President & Head of Research, Pliant Therapeutics Inc.


  • Highlighting the discovery and development of PLN-74809, a dual selective integrin inhibitor for pulmonary fibrosis
  • Uncovering Pliant’s translational approach and successful Phase 2 results in IPF
  • Reprogramming the tumor microenvironment with selective inhibition of TGF-β
  • Discussing blocking integrin activation of TGF-β to increase checkpoint inhibitor efficacy and targeting immune and stromal activation of TGF-β

9:30 am Illuminating the TGF-β for Immuno-Oncology Landscape


  • Revealing the preclinical studies of TGF-β for the oncology field
  • Outlining TGF-β therapeutics that are being considered in the context of combinations

10:00 am
Speed Networking


  • This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the TGF-β for immuno-oncology field
  • Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into pioneering work

10:45 am
Morning Break & Networking

11:00 am Reimagining the TGF-β Landscape: Moving Forward to Therapeutic Success


  • Session Overview To Be Confirmed

11:30 am Discussion Panel: Forecasting the Future Developments in Targeting TGF-β for Immuno-Oncology: Where May the Next 3-5 Years Take Us?

12:00 pm

Assessing the Clinical Challenges on the Journey to Safely & Successfully Unlocking the Therapeutic Potential of TGF-β for IO

1:00 pm Discussion Panel: What Are the Most Important Considerations to Move Past the Failures & Have Success in the Clinic?

1:40 pm Leveraging the Lessons from Past Drug Development Experiences


  • Exploring the degree of inhibition to achieve clinically meaningful outcomes
  • Using preclinical data to predict target modulation and efficacy in patients
  • Navigating alternative pathways to target TGF-β signalling, including blocking the enzyme autotaxin

2:10 pm
Afternoon Break & Poster Session


  • Connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships, whilst exploring the latest in TGF-β for Immuno-Oncology therapeutic advances
  • To submit a poster, or to find out more, contact info@hansonwade.com

3:10 pm Audience Roundtable Discussions: Discussing the Learnings from the Clinical Studies to Ensure Future TGF-β for Immuno-Oncology Therapeutic Success


  • This session will facilitate in-depth discussion between participants in an informal environment to absorb, consolidate, and implement the lessons learned from the morning sessions; and to discuss what this means for the next 5 years of TGF-β for immuno-oncology therapeutics
  • Deciphering the lessons learned from the recent clinical failures to design effective future preclinical and clinical studies to supercharge TGF-β therapeutics to patients in need

Selecting Targets Within the TGF-β Pathway

Pros & Cons of Therapeutic Modalities: How to Improve the Therapeutic Index?

Combination Therapies: Where to Add TGF-β Into Standard of Care?

Biomarker & PD Readouts for the Therapeutic Impact on Tumor Cells & Immune Cells

Considering Pre-Clinical Models that Best Predict Clinical Success

Tumor Type & Cell Type Specific Considerations for Target & Modality Selection

4:00 pm SRK-181, A Latent TGF-β Inhibitor: Safety & Efficacy Results From the Dose Escalation Portion of a Phase I Trial (DRAGON Trial) in Patients with Advanced Solid Tumors

  • Lu Gan Senior Director - Medical, X4 Pharmaceuticals


  • Exploring the SRK-181 mechanism of action and study design
  • Navigating dose escalation and safety data to determine how high the dose and what the safety profile of the therapeutic looks like

4:30 pm Chair’s Closing Remarks